File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.vaccine.2016.03.032
- Scopus: eid_2-s2.0-84961827497
- WOS: WOS:000375507800002
Supplementary
- Citations:
- Appears in Collections:
Article: Hospital-based vaccine effectiveness against influenza B lineages, Hong Kong, 2009−14
Title | Hospital-based vaccine effectiveness against influenza B lineages, Hong Kong, 2009−14 |
---|---|
Authors | |
Keywords | Children Hospitalization Influenza B Lineage specific Triavalent influenza vaccine Vaccine effectiveness |
Issue Date | 2016 |
Citation | Vaccine, 2016, v. 34 n. 19, p. 2164-2169 How to Cite? |
Abstract | BACKGROUND: We estimated vaccine effectiveness (VE) against pediatric influenza B hospitalizations in Hong Kong year round between November 2001 and October 2014. METHODS: We conducted a test-negative year-round study, enrolling children 6 months to 17 years of age admitted to two hospitals in Hong Kong with a febrile acute respiratory infection. Children were tested for influenza A and B. Conditional logistic regression was used to estimate overall and lineage-specific vaccine effectiveness comparing influenza vaccination history of the trivalent influenza vaccine (TIV) among patients testing positive for influenza B versus negative for influenza A and B, adjusting for age and sex and matching by calendar week of recruitment. RESULTS: Of the 6013 children included in the analysis, 262 tested positive for influenza B. Vaccination coverage was low: 6.5% in the influenza B positive children when compared with 8.8% in children who tested negative for both influenza A and B (p=0.248). Overall, VE was 47.6% (95% CI: 10.0, 69.4%) against influenza B hospitalization despite variable co-circulation of both lineages in all years. VE for Victoria-like virus calculated from 3 years when the vaccine was lineage-matched was 59.1% (95% CI: 6.2, 82.2%). Lineage-matched VE for Yamagata-like virus was -8.8% (95% CI: -215.4, 62.5%) in a clade mismatch season. With wide confidence intervals, we were unable to demonstrate cross-lineage protection: VE against the mismatched B/Yamagata-like virus was 9.5% (95% CI: -240.4, 76.0%) in 2011/12 and against mismatched B/Victoria-like virus in 2013/14 was 42.7% (95% CI: -368.6, 93.0%). CONCLUSIONS: TIV conferred an overall VE of 47.6% (95% CI: 10.0, 69.4%) against influenza B hospitalization in children despite variable co-circulation of both lineages in all years. Lineage-matched VE for Yamagata-like virus was poor and may be related to clade mismatch. Cross-lineage protection was not observed. |
Persistent Identifier | http://hdl.handle.net/10722/226633 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chiu, SSS | - |
dc.contributor.author | Nicholls, JM | - |
dc.contributor.author | Chan, KH | - |
dc.contributor.author | Lo, JY | - |
dc.contributor.author | Chan, LY | - |
dc.contributor.author | So, LY | - |
dc.contributor.author | Cowling, BJ | - |
dc.contributor.author | Peiris, JSM | - |
dc.date.accessioned | 2016-06-17T07:45:20Z | - |
dc.date.available | 2016-06-17T07:45:20Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Vaccine, 2016, v. 34 n. 19, p. 2164-2169 | - |
dc.identifier.uri | http://hdl.handle.net/10722/226633 | - |
dc.description.abstract | BACKGROUND: We estimated vaccine effectiveness (VE) against pediatric influenza B hospitalizations in Hong Kong year round between November 2001 and October 2014. METHODS: We conducted a test-negative year-round study, enrolling children 6 months to 17 years of age admitted to two hospitals in Hong Kong with a febrile acute respiratory infection. Children were tested for influenza A and B. Conditional logistic regression was used to estimate overall and lineage-specific vaccine effectiveness comparing influenza vaccination history of the trivalent influenza vaccine (TIV) among patients testing positive for influenza B versus negative for influenza A and B, adjusting for age and sex and matching by calendar week of recruitment. RESULTS: Of the 6013 children included in the analysis, 262 tested positive for influenza B. Vaccination coverage was low: 6.5% in the influenza B positive children when compared with 8.8% in children who tested negative for both influenza A and B (p=0.248). Overall, VE was 47.6% (95% CI: 10.0, 69.4%) against influenza B hospitalization despite variable co-circulation of both lineages in all years. VE for Victoria-like virus calculated from 3 years when the vaccine was lineage-matched was 59.1% (95% CI: 6.2, 82.2%). Lineage-matched VE for Yamagata-like virus was -8.8% (95% CI: -215.4, 62.5%) in a clade mismatch season. With wide confidence intervals, we were unable to demonstrate cross-lineage protection: VE against the mismatched B/Yamagata-like virus was 9.5% (95% CI: -240.4, 76.0%) in 2011/12 and against mismatched B/Victoria-like virus in 2013/14 was 42.7% (95% CI: -368.6, 93.0%). CONCLUSIONS: TIV conferred an overall VE of 47.6% (95% CI: 10.0, 69.4%) against influenza B hospitalization in children despite variable co-circulation of both lineages in all years. Lineage-matched VE for Yamagata-like virus was poor and may be related to clade mismatch. Cross-lineage protection was not observed. | - |
dc.language | eng | - |
dc.relation.ispartof | Vaccine | - |
dc.subject | Children | - |
dc.subject | Hospitalization | - |
dc.subject | Influenza B | - |
dc.subject | Lineage specific | - |
dc.subject | Triavalent influenza vaccine | - |
dc.subject | Vaccine effectiveness | - |
dc.title | Hospital-based vaccine effectiveness against influenza B lineages, Hong Kong, 2009−14 | - |
dc.type | Article | - |
dc.identifier.email | Chiu, SSS: ssschiu@hku.hk | - |
dc.identifier.email | Nicholls, JM: jmnichol@hkucc.hku.hk | - |
dc.identifier.email | Chan, KH: chankh2@hkucc.hku.hk | - |
dc.identifier.email | Chan, LY: laiyin@hkucc.hku.hk | - |
dc.identifier.email | Cowling, BJ: bcowling@hku.hk | - |
dc.identifier.email | Peiris, JSM: malik@hkucc.hku.hk | - |
dc.identifier.authority | Chiu, SSS=rp00421 | - |
dc.identifier.authority | Nicholls, JM=rp00364 | - |
dc.identifier.authority | Chan, KH=rp01921 | - |
dc.identifier.authority | Cowling, BJ=rp01326 | - |
dc.identifier.authority | Peiris, JSM=rp00410 | - |
dc.identifier.doi | 10.1016/j.vaccine.2016.03.032 | - |
dc.identifier.scopus | eid_2-s2.0-84961827497 | - |
dc.identifier.hkuros | 258354 | - |
dc.identifier.volume | 34 | - |
dc.identifier.issue | 19 | - |
dc.identifier.spage | 2164 | - |
dc.identifier.epage | 2169 | - |
dc.identifier.isi | WOS:000375507800002 | - |